Patents by Inventor Marcin Tomasz Kortylewski

Marcin Tomasz Kortylewski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CTLA-4 aptamer conjugates
    Patent number: 11912995
    Abstract: Provided herein are, inter alia, nucleic acid compounds useful for targeting CTLA-4-expressing cells and modulating cell activity of the CTLA-4-expressing cells. The compositions provided herein may be part of pharmaceutical compositions and may be used for treatment of cancer, inflammatory diseases, infectious diseases or metabolic diseases.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: February 27, 2024
    Assignee: City of Hope
    Inventors: Hua Yu, Andreas Herrmann, Marcin Tomasz Kortylewski, Piotr Marek Swiderski
  • Methods of using anti-MIR126 compounds
    Patent number: 11801266
    Abstract: Provided herein are, inter alia, methods of treating red blood cell disorders and cancer using anti-miR126 compounds. The methods include administering phosphorothioated CpG oligodeoxynucleotides conjugated to an anti-miR126 nucleic acid sequence to treat red blood cell disorders. Other methods provided herein include administering phosphorothioated CpG oligodeoxynucleotides conjugated to an anti-miR126 nucleic acid sequence and a tyrosine kinase inhibitor to treat cancer.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: October 31, 2023
    Assignee: CITY OF HOPE
    Inventors: Guido Marcucci, Bin Zhang, Ya-Huei Kuo, Marcin Tomasz Kortylewski
  • COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF
    Publication number: 20230340479
    Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.
    Type: Application
    Filed: February 8, 2023
    Publication date: October 26, 2023
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Guido Marcucci, Bin Zhang, Ya-Huei Kuo
  • MICRORNA AS A THERAPEUTIC AGENT
    Publication number: 20230220385
    Abstract: The disclosure provides, inter alia, hybridized nucleic acid sequences and compounds comprising Toll-like receptor 9-binding nucleic acid sequences and nucleic acid sequences comprising a microRNA passenger strand sequence hybridized to a microRNA guide strand sequence; pharmaceutical compositions comprising the hybridized nucleic acid sequences and compounds; and the use of the hybridized nucleic acid sequences, compounds, and pharmaceutical compositions to treat medical conditions, such as cancer and inflammatory diseases.
    Type: Application
    Filed: November 25, 2020
    Publication date: July 13, 2023
    Inventors: Marcin Tomasz Kortylewski, Guido Marcucci, Yu-Lin Su, Piotr Marek Swiderski
  • MULTI-CONJUGATES COMPRISING MULTIPLE LIGANDS
    Publication number: 20230203085
    Abstract: A multi-conjugate comprising two or more covalently linked biological subunits, wherein at least two of the subunits are terminally located targeting ligands. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutic agent that is the multi-conjugate is also disclosed. The multi-conjugate may be administered to a subject for providing treatment or prophylaxis against a disease or other medical condition.
    Type: Application
    Filed: September 1, 2022
    Publication date: June 29, 2023
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Jonathan Miles Brown, Kristin K.H. Neuman
  • Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
    Patent number: 11591596
    Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: February 28, 2023
    Assignee: City of Hope
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Guido Marcucci, Bin Zhang, Ya-Huei Kuo
  • COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF
    Publication number: 20220401563
    Abstract: The present disclosure relates to an isolated compound including a phosphorothioated oligodeoxynucleotide (ODN) sequence conjugated to a short-activating RNA (saRNA) or an antisense oligonucleotide sequence (ASO), compositions of such a compound, and method of treatment of cancer and autoimmune diseases (with or without stimulating an immune response), method of immune stimulation, method of activating CEBPA, and method of reducing activity of STAT transcription factor, by one of the disclosed compounds or compositions.
    Type: Application
    Filed: July 14, 2022
    Publication date: December 22, 2022
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Dayson Friaca Moreira
  • Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
    Patent number: 11464865
    Abstract: The present disclosure relates to an isolated compound including a phosphorothioated oligodeoxynucleotide (ODN) sequence conjugated to a short-activating RNA (saRNA) or an antisense oligonucleotide sequence (ASO), compositions of such a compound, and method of treatment of cancer and autoimmune diseases (with or without stimulating immune response), method of immune stimulation, method of activating CEBPA, and method of reducing activity of STAT transcription factor, by one of the disclosed compounds or compositions.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: October 11, 2022
    Assignee: CITY OF HOPE
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Dayson Friaca Moreira
  • CTLA-4 APTAMER CONJUGATES
    Publication number: 20220145299
    Abstract: Provided herein are, inter alia, nucleic acid compounds useful for targeting CTLA-4-expressing cells and modulating cell activity of the CTLA-4-expressing cells. The compositions provided herein may be part of pharmaceutical compositions and may be used for treatment of cancer, inflammatory diseases, infectious diseases or metabolic diseases.
    Type: Application
    Filed: October 25, 2021
    Publication date: May 12, 2022
    Inventors: Hua YU, Andreas HERRMANN, Marcin Tomasz KORTYLEWSKI
  • OLIGONUCLEOTIDE INHIBITORS OF NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS AND THE USES THEREOF
    Publication number: 20220002730
    Abstract: Disclosed herein, inter alia, are oligonucleotide inhibitors of the Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-?B) signaling pathway and methods of use thereof.
    Type: Application
    Filed: August 23, 2019
    Publication date: January 6, 2022
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski
  • CTLA-4 aptamer conjugates
    Patent number: 11186840
    Abstract: Provided herein are, inter alia, nucleic acid compounds useful for targeting CTLA-4-expressing cells and modulating cell activity of the CTLA-4-expressing cells. The compositions provided herein may be part of pharmaceutical compositions and may be used for treatment of cancer, inflammatory diseases, infectious diseases or metabolic diseases.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: November 30, 2021
    Assignee: CITY OF HOPE
    Inventors: Hua Yu, Andreas Herrmann, Marcin Tomasz Kortylewski
  • STAT3 INHIBITORS AND USES THEREOF
    Publication number: 20210207142
    Abstract: Described herein, inter alia, are STAT-binding nucleic acids-including compositions and methods of using the same.
    Type: Application
    Filed: October 14, 2020
    Publication date: July 8, 2021
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski
  • COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF
    Publication number: 20210115443
    Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.
    Type: Application
    Filed: September 2, 2020
    Publication date: April 22, 2021
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Guido Marcucci, Bin Zhang, Ya-Huei Kuo
  • NEURAL STEM CELL DELIVERY OF THERAPEUTIC AGENTS
    Publication number: 20210077535
    Abstract: The disclosure provides, inter alia, neural stem cells comprising exogenous nucleotides, vesicles comprising exogenous nucleotides, and methods for treating diseases and disorders, such as cancer, neurodegenerative diseases, inflammatory diseases, and viral diseases, using the neural stem cells, vesicles, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: August 21, 2020
    Publication date: March 18, 2021
    Inventors: Marcin Tomasz Kortylewski, Karen Aboody, Alexandra Jacqueline Annala, Mohamed Hammad
  • COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF
    Publication number: 20210038733
    Abstract: The present disclosure relates to an isolated compound including a phosphorothioated oligodeoxynucleotide (ODN) sequence conjugated to a short-activating RNA (saRNA) or an antisense oligonucleotide sequence (ASO), compositions of such a compound, and method of treatment of cancer and autoimmune diseases (with or without stimulating immune response), method of immune stimulation, method of activating CEBPA, and method of reducing activity of STAT transcription factor, by one of the disclosed compounds or compositions.
    Type: Application
    Filed: July 24, 2020
    Publication date: February 11, 2021
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Dayson Friaca Moreira
  • CTLA-4 APTAMER CONJUGATES
    Publication number: 20200377890
    Abstract: Provided herein are, inter alfa, nucleic acid compounds useful for targeting CTLA-4-expressing cells and modulating cell activity of the CTLA-4-expressing cells. The compositions provided herein may be part of pharamceutcial compositions and may be used for treatment of cancer, inflammatory diseases, infectious diseases or metabolic diseases.
    Type: Application
    Filed: June 4, 2020
    Publication date: December 3, 2020
    Inventors: Hua YU, Andreas HERRMANN, Marcin Tomasz KORTYLEWSKI
  • STAT3 inhibitors and uses thereof
    Patent number: 10829765
    Abstract: Described herein, inter alia, are STAT-binding nucleic acids-including compositions and methods of using the same.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: November 10, 2020
    Assignee: CITY OF HOPE
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski
  • Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
    Patent number: 10801026
    Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: October 13, 2020
    Assignee: CITY OF HOPE
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Guido Marcucci, Bin Zhang, Ya-Huei Kuo
  • METHODS OF USING ANTI-MIR126 COMPOUNDS
    Publication number: 20200281982
    Abstract: Provided herein are, inter alia, methods of treating red blood cell disorders and cancer using anti-miR126 compounds. The methods include administering phosphorothioated CpG oligodeoxynucleotides conjugated to an anti-miR126 nucleic acid sequence to treat red blood cell disorders. Other methods provided herein include administering phosphorothioated CpG oligodeoxynucleotides conjugated to an anti-miR126 nucleic acid sequence and a tyrosine kinase inhibitor to treat cancer.
    Type: Application
    Filed: March 5, 2020
    Publication date: September 10, 2020
    Inventors: Guido Marcucci, Bin Zhang, Ya-Huei Kuo, Marcin Tomasz Kortylewski
  • Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
    Patent number: 10758624
    Abstract: The present disclosure relates to an isolated compound including a phosphorothioated oligodeoxynucleotide (ODN) sequence conjugated to a short-activating RNA (saRNA) or an antisense oligonucleotide sequence (ASO), compositions of such a compound, and method of treatment of cancer and autoimmune diseases (with or without stimulating immune response), method of immune stimulation, method of activating CEBPA, and method of reducing activity of STAT transcription factor, by one of the disclosed compounds or compositions.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: September 1, 2020
    Assignee: CITY OF HOPE
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Dayson Friaca Moreira